Literature DB >> 12488296

Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.

P Morice1, D Brehier-Ollive, A Rey, D Atallah, C Lhommé, P Pautier, C Pomel, S Camatte, P Duvillard, D Castaigne.   

Abstract

BACKGROUND: To study the results of interval debulking surgery (IDS) in patients treated for 'unresectable' advanced stage ovarian cancer compared with primary debulking surgery (PDS) followed by chemotherapy. PATIENTS AND METHODS: An exposed-non-exposed study including a group of 34 patients who underwent an IDS and were matched to an historic control group of 34 patients treated with PDS.
RESULTS: Optimal cytoreductive surgery was achieved in 94% (32 out of 34) of patients in both groups. The rates of post-operative morbidity, blood transfusion and median length of hospitalisation were significantly reduced in the study (IDS) group, but survival did not differ in both groups.
CONCLUSIONS: IDS in patients with advanced stage ovarian cancer offers the same chance of survival as PDS, but it is better tolerated.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12488296     DOI： 10.1093/annonc/mdg003

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  11 in total

1.  The optimal time for surgery in women with serous ovarian cancer.

Authors:  Jocelyn M Stewart; Alicia A Tone; Haiyan Jiang; Marcus Q Bernardini; Sarah Ferguson; Stephane Laframboise; K Joan Murphy; Barry Rosen; Taymaa May
Journal:  Can J Surg       Date:  2016-08       Impact factor: 2.089

2.  Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.

Authors:  Melissa M Thrall; Heidi J Gray; Rebecca Gaston Symons; Noel S Weiss; David R Flum; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2011-09-26       Impact factor: 5.482

Review 3.  The Significance of Peritoneal Washing as a Prognostic Indicator for Ovarian Cancer Patients.

Authors:  Christina Christou; Sevasti-Effraimia Krouskou; Antonios Koutras; Thomas Ntounis; Zacharias Fasoulakis; Asimina Valsamaki; Vasilios Pergialiotis; Sotirios Sotiriou; Kyriakos Konis; Panagiotis Symeonidis; Athina A Samara; Athanasios Pagkalos; Athanasios Chionis; Georgios Daskalakis; Emmanuel N Kontomanolis
Journal:  Cancer Diagn Progn       Date:  2022-09-03

Review 4.  The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.

Authors:  Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-16

5.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.

Authors:  Katherine R Kozak; Malaika W Amneus; Suzanne M Pusey; Feng Su; Mui N Luong; Sam A Luong; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

6.  Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers.

Authors:  Yong-Wan Kim; Su Mi Bae; Hyunsun Lim; Yoon Ji Kim; Woong Shick Ahn
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

7.  Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients.

Authors:  Arturas Inciura; Andrius Simavicius; Elona Juozaityte; Juozas Kurtinaitis; Ruta Nadisauskiene; Eimantas Svedas; Skirmantas Kajenas
Journal:  BMC Cancer       Date:  2006-06-08       Impact factor: 4.430

8.  Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?

Authors:  I Vandenput; B Van Calster; A Capoen; K Leunen; P Berteloot; P Neven; Ph Moerman; I Vergote; F Amant
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

9.  The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.

Authors:  Karina Biskup; Elena Iona Braicu; Jalid Sehouli; Rudolf Tauber; Véronique Blanchard
Journal:  Dis Markers       Date:  2014-08-12       Impact factor: 3.434

10.  Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.

Authors:  Upasana Baruah; Debabrata Barmon; Amal Chandra Kataki; Pankaj Deka; Munlima Hazarika; Bhargab J Saikia
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.